Therapeutic Drug Monitoring in Inflammatory Bowel Disease History and Future Directions

被引：16
作者：
Spencer, Elizabeth A. [1 ]
Dubinsky, Marla C. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Pediat Gastroenterol & Hepatol, Dept Pediat, Susan & Leonard Feinstein IBD Clin Ctr,Mt Sinai H, 1 Gustave L Levy Pl,Box 1656, New York, NY 10029 USA
来源：
PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 06期
关键词：
Inflammatory bowel disease; Therapeutic drug monitoring; Thiopurine metabolite monitoring; Biologics; SEVERE ULCERATIVE-COLITIS; ANTI-TNF THERAPY; THIOPURINE S-METHYLTRANSFERASE; PATIENTS LOSING RESPONSE; INFLIXIMAB TROUGH LEVELS; QUALITY-OF-LIFE; CROHNS-DISEASE; MAINTENANCE THERAPY; PEDIATRIC-PATIENTS; INDUCTION THERAPY;
D O I：
10.1016/j.pcl.2017.08.008
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease (IBD) have shown only a 50% to 60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not used in these trials. This article details the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems.
引用
收藏
页码：1309 / +
页数：19
相关论文
共 97 条
[21]   A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis [J].
D'Haens, Geert ;
Sandborn, William J. ;
Feagan, Brian G. ;
Geboes, Karel ;
Hanauer, Stephen B. ;
Irvine, E. Jan ;
Lemann, Marc ;
Marteau, Philippe ;
Rutgeerts, Paul ;
Scholmerich, Jurgen ;
Sutherland, Lloyd R. .
GASTROENTEROLOGY, 2007, 132 (02) :763-786
[22]   The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response [J].
D'Haens, Geert R. ;
Panaccione, Remo ;
Higgins, Peter D. R. ;
Vermeire, Severine ;
Gassull, Miquel ;
Chowers, Yehuda ;
Hanauer, Stephen B. ;
Herfarth, Hans ;
Hommes, Daan W. ;
Kamm, Michael ;
Lofberg, Robert ;
Quary, A. ;
Sands, Bruce ;
Sood, A. ;
Watermayer, G. ;
Lashner, Bret ;
Lemann, Marc ;
Plevy, Scott ;
Reinisch, Walter ;
Schreiber, Stefan ;
Siegel, Corey ;
Targan, Stephen ;
Watanabe, M. ;
Feagan, Brian ;
Sandborn, William J. ;
Colombel, Jean Frederic ;
Travis, Simon .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (02) :199-212
[23]   Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease [J].
Davidov, Yana ;
Ungar, Bella ;
Bar-Yoseph, Haggai ;
Carter, Dan ;
Haj-Natour, Ola ;
Yavzori, Miri ;
Chowers, Yehuda ;
Eliakim, Rami ;
Ben-Horin, Shomron ;
Kopylov, Uri .
JOURNAL OF CROHNS & COLITIS, 2017, 11 (05) :549-555
[24]   Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
Curvers, WL ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :311-318
[25]   Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis [J].
Detrez, Iris ;
Dreesen, Erwin ;
Van Stappen, Thomas ;
de Vries, Annick ;
Brouwers, Els ;
Van Assche, Gert ;
Vermeire, Severine ;
Ferrante, Marc ;
Gils, Ann .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (05) :575-581
[26]   Azathioprine, 6-Mercaptopurine in Inflammatory Bowel Disease: Pharmacology, Efficacy, and Safety [J].
Dubinsky, Marla C. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (09) :731-743
[27]   Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients [J].
Dubinsky, Marla C. ;
Phan, Becky L. ;
Singh, Namita ;
Rabizadeh, Shervin ;
Mould, Diane R. .
AAPS JOURNAL, 2017, 19 (01) :215-222
[28]   Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease [J].
Dubinsky, Marla C. ;
Rosh, Joel ;
Faubion, William A. ;
Kierkus, Jaroslaw ;
Ruemmele, Frank ;
Hyams, Jeffrey S. ;
Eichner, Samantha ;
Li, Yao ;
Huang, Bidan ;
Mostafa, Nael M. ;
Lazar, Andreas ;
Thakkar, Roopal B. .
INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) :886-893
[29]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[30]   6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease [J].
Dubinsky, MC ;
Yang, HY ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
GASTROENTEROLOGY, 2002, 122 (04) :904-915
12345678910